Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,400.09 -17.59 -0.12%
TOPIX 1,166.94 0.39 0.03%
HANG SENG 22,749.87 53.86 0.24%

The Zacks Analyst Blog Highlights:Novo Nordisk, Sanofi, Eli Lilly, Merck and Johnson & Johnson



 The Zacks Analyst Blog Highlights:Novo Nordisk, Sanofi, Eli Lilly, Merck and
                              Johnson & Johnson

PR Newswire

CHICAGO, Dec. 21, 2012

CHICAGO, Dec. 21, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Novo Nordisk (NYSE:NVO), Sanofi
(NYSE:SNY), Eli Lilly and Company (NYSE:LLY), Merck & Co. Inc. (NYSE:MRK) and
Johnson & Johnson (NYSE:JNJ).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Thursday's Analyst Blog:

Novo Progresses with Pipeline

Novo Nordisk (NYSE:NVO) recently completed a phase IIIa study on IDegLira,
which is a combination of Tresiba (insulin degludec) and Victoza
(liraglutide). Novo Nordisk is evaluating IDegLira for the treatment of
patients suffering from type II diabetes.

The phase III study (DUAL II) enrolled around 400 patients suffering from type
II diabetes and previously insufficiently controlled on basal insulin in
combination with 1–2 oral anti-diabetic agents. The study results showed that
patients treated with IDegLira or Tresiba plus metformin achieved superiority
compared to standalone therapy with Tresiba.

The study revealed that around 60% of the patients who used IDegLira achieved
the HbA1c target of 7% (recommended by the American Diabetes Association and
the European Association for the Study of Diabetes). Moreover, 45% of the
patients reached the HbA1c target of 6.5% (recommended by the American Academy
of Clinical Endocrinology).

Both IDegLira and Tresiba have been reported safe and tolerable. Novo Nordisk
did not report any disparity between the two treatment arms as to adverse
reactions and normal safety parameters.

We note that Novo Nordisk had announced results from the first phase IIIa
trial of IDegLira, DUAL I, in August this year, which demonstrated an
impressive efficacy profile. Novo Nordisk now plans to file regulatory
applications in both the US and the EU in 2013.

Although Novo Nordisk holds a strong position in the diabetes market, we note
that the diabetes market is highly crowded with players like Sanofi
(NYSE:SNY), Eli Lilly and Company (NYSE:LLY) and Merck & Co. Inc. (NYSE:MRK).

We have an Outperform recommendation on Denmark-based Novo Nordisk. The stock
carries a Zacks #2 Rank (Buy). Other large cap pharma company, that carry a
Zacks #2 Rank  is Johnson & Johnson (NYSE:JNJ).

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement